A new study demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a ...
A study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of the University of Pennsylvania ...
Researchers at the Francis Crick Institute, the UCL Cancer Institute and UCLH have shown that a test called ORACLE can ...
Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery ...
Background Heart failure (HF) guidelines recommend routine testing for iron deficiency (ID) and, for those with ID, ...
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Trial underscores IROS's commitment to developing innovative therapies for unmet medical needs <li /> The study's success ...
An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...
The global artificial intelligence in clinical trials market, valued at US$1.20 billion in 2023, is forecasted to grow at a ...
US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...
A multidisciplinary team of University of Miami researchers studying factors associated with health outcomes and disease risk in the Hispanic community has received a $21 million grant from the ...
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete response rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback